NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Moleculin Biotech, Inc. (MBRX) Stock Analysis

Moleculin Biotech, Inc. (MBRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MBRX

$0.71

+$0.03 (+5.03%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MBRX with… →

MBRX Key Statistics

As of Sep 4, 2026
Trading
Open
$0.69
Previous Close
$0.68
Day's Range
0.68–0.74
52-Week Range
0.16–15.75
Volume
768.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.92
Valuation
Market Cap
$13.83M
P/E Ratio
0.05
EPS (ttm)Profit attributable to each share over the last twelve months.
15.40
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$33.56M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
19.48M
1-Year Return
−92.51%
Dividend and dates
Avg Volume
1.26M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MBRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−78.55%
2025−92.21%
2024−86.79%
2023−19.06%
2022−43.01%
2021−61.10%
2020−12.90%
2019−12.02%
2018−44.09%
2017−18.42%
2016 (partial year)−65.02%

As of September 4, 2026.

MBRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$33.56M—
2024$0.00−$26.05M—
2023$0.00−$29.77M—
2022$0.00−$29.03M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$25.10M−$33.56M—
2024$0.00—−$26.64M−$26.05M—
2023$0.00—−$29.63M−$29.77M—
2022$0.00—−$30.64M−$29.03M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MBRX Valuation vs Biotechnology Median

Median of 656 stocks
MetricMBRXBiotechnology medianvs median
P/E0.0512.570.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Moleculin Biotech, Inc. (MBRX) at $13.83M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 17.

MBRX last closed at $0.71 on September 4, 2026. That is +$0.03 (+5.03%) against the previous close. Over the past 52 weeks the price has ranged from $0.16 to $15.75. The latest close sits 340.99% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $33.56M. The reported profit margin is 0%. Trailing earnings per share are 15.4.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 0.05 times earnings. That is 0 times the Biotechnology median of 12.57. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.92. Daily returns over the trailing 10 years annualize to a volatility of 141.74%. The trailing one-year price return is −92.51%. Across 10 years the annualized return works out at −62.88%.

Growth & Income

The record shows no dividend for MBRX.

2026 is still running; the price is −78.55% year to date. Across the complete calendar years on file, 2019 returned −12.02% and 2025 returned −92.21%. Of the 9 complete calendar years on file, 0 finished higher.

Peer Comparison

Moleculin Biotech, Inc. (MBRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Moleculin Biotech, Inc. MBRX $13.83M 0.1
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Moleculin Biotech, Inc. trades at a P/E of 0.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Visit website →